SRC and renal cell carcinoma: The initial high-throughput drug screen and subsequent 2D and 3D spheroid-based validations highlighted the PI3K/mTOR inhibitor NVP-BGT226, the RNA synthesis inhibitor Mithramycin A, and the SRC inhibitor Dasatinib as promising therapies for MiT-RCC.